CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia

Launched by ZHEJIANG UNIVERSITY · Oct 8, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach for patients with severe aplastic anemia, a serious condition where the bone marrow doesn't produce enough blood cells. The study is focused on using a therapy called CD7 CAR-T, which aims to prepare patients for a stem cell transplant from a suitable donor. The primary goal is to assess how safe this treatment is for patients who may not be able to undergo traditional stem cell transplants.

To be eligible for this trial, participants must be diagnosed with severe aplastic anemia and have specific blood characteristics indicating a low number of blood cells. They should also be willing to receive treatment and meet certain health criteria, such as having a good kidney function and no active infections. If you or a loved one participates, you can expect to receive a new type of therapy that could potentially help bridge the gap to a stem cell transplant, along with regular monitoring by healthcare professionals. It's important to note that this trial is still recruiting participants and is focused on safety, so there may be some unknowns about the long-term effects of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chinese expert consensus on the diagnosis and treatment of aplastic anemia（2017）, Diagnosis of severe aplastic anemia ，1. The degree of bone marrow cell proliferation \< 25%, or 25%-50% but residual hematopoietic cells \< 30%；2. With pancytopenia (at least two of the following peripheral blood parameters) : (1) absolute neutrophil \<0.5×10\^9/L; (2) Platelet count\< 20×10\^9/L; (3) The absolute value of reticulocytes \<20×109/L;
• • Suitable donors (relatives) with allogeneic HSCT indications and at least haploid allogeneic transplantation;
• • Patients who are not suitable or unwilling to undergo traditional allogeneic hematopoietic stem cell transplantation;
• • creatinine clearance \> 60ml/min; without liver invasion, serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range. If there is liver invasion, serum erythrambirubin ≤ 3 times the upper limit of normal, and serum ALT and AST are both ≤ 5 times the upper limit of the normal range;
• • Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
• • No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
• • Estimated survival time ≥ 3 months;
• • ECOG performance status 0 to 1;
• • Females and males of childbearing potential must agree to use adequate contraception prior to study entry, during study participation, and for 6 months after infusion (the safety of this therapy for unborn children is not known and has unknown risks);
• • Those who voluntarily participated in this trial and provided informed consent;
• Exclusion Criteria:
• • Allergy to pre-treatment measures；
• • Those with acute graft versus host disease (GvHD) or moderate to severe chronic GvHD within 4 weeks before screening; Those who have received systemic drug therapy for GvHD within 4 weeks before the reinfusion；
• • History of epilepsy or other central nervous system disorders；
• • Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
• • Less than 100 days after allogeneic hematopoietic stem cell transplantation；
• • Patients with HIV infection，Active infection of hepatitis B virus or hepatitis C virus，Uncured active infection；
• • The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
• • Received anti-cancer chemotherapy or other drug treatment within 2 weeks prior to screening;
• • Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the study.